AbbVie (NYSE: ABBV) has expanded its collaboration with Scripps Research’s Calibr-Skaggs Institute, securing licensing rights to the institute’s investigational switchable CAR-T (sCAR-T) platform, which has shown promising early-stage results. The agreement entails an upfront payment, along with potential milestone payments and royalties, allowing AbbVie to access the program for up to five years. The deal also includes options to license existing candidates targeting hematological and solid tumors, as well as to investigate the platform’s applications in autoimmune diseases.
The sCAR-T technology utilizes an antibody to mediate the interaction between antigen receptors in CAR-T therapies and pathogenic cells, facilitating controlled activation of the treatment within the body. This innovative approach aims to mitigate the toxicities linked to CAR-T overactivation while potentially improving efficacy in solid tumors.- Flcube.com
